Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Recruiting · NCT06762769 · Registry updated 2025-08-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Phase 2 | 2025-08-01 | NCT06762769 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol Myers Squibb Pharmaceuticals Limited | 1 |
| Sanofi | 254 |
| University College, London | 222 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Barts Health Trust | London | United Kingdom | 1 |
| Nottingham City Hospital | Nottingham | United Kingdom | 30 |